Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [41] Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
    Huang, Qing
    Emond, Bruno
    Lafeuille, Marie-Helene
    Gupta, Deepshekhar
    Lefebvre, Patrick
    Sundaram, Murali
    Mato, Anthony
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (12) : 2009 - 2018
  • [42] Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Abrisqueta, Pau
    Lopez-Jimenez, Javier
    Osorio, Santiago
    Hernandez Rivas, Jose Angel
    de la Cruz, Fatima
    Magnano, Laura
    Maria Arguinano, Jose
    Gonzalez, Marcos
    de la Serna, Javier
    Szoke, Anita
    Neumayr, Lynne D.
    Diels, Joris
    Schioppa, Claudio A.
    Rubio Azpeitia, Eva
    Dominguez-Lubillo, Teresa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S359 - S359
  • [43] Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy
    Sanford, David
    Desjardins, Pierre
    Leber, Brian
    Paulson, Kristjan
    Assouline, Sarit
    Lembo, Paola M. C.
    Fournier, Pierre-Andre
    Leitch, Heather A.
    CURRENT ONCOLOGY, 2022, 29 (10) : 6794 - 6806
  • [44] Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI
    Roeker, Lindsey E.
    Burke, John M.
    Rhodes, Joanna M.
    Emechebe, Nnadozie
    Jawaid, Dureshahwar
    Manzoor, Beenish S.
    Jensen, Christopher E.
    Ryland, Lindsay
    Liu, Yangyang
    Marx, Steve E.
    Sinai, Wendy
    Roser, Jordan
    Shadman, Mazyar
    CANCERS, 2025, 17 (05)
  • [45] Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia
    Nazir, Adil
    Fawad
    Ali, Sheeraz
    Badar, Farhana
    Siddique, Neelam
    Hameed, Abdul
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2016, 32 (05) : 1213 - 1217
  • [46] Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario
    Seung, Soo Jin
    Hurry, Manjusha
    Hassan, Shazia
    Elnoursi, Ashlie
    Scheider, Krystin A. B.
    Wagner, Dennis
    Edwin, Jonathan J.
    Aw, Andrew T. W.
    CURRENT ONCOLOGY, 2021, 28 (06) : 4832 - 4844
  • [47] Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Suzy Van Sanden
    Simona Baculea
    Joris Diels
    Sarah Cote
    Advances in Therapy, 2017, 34 : 1650 - 1661
  • [48] Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center
    Ranti, Juha
    Perkonoja, Katariina
    Kauko, Tommi
    Loponen, Heidi
    Joensuu, Emmi I.
    Jarvinen, Tiina M.
    EJHAEM, 2022, 3 (01): : 291 - 300
  • [49] Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
    Mauro, Francesca Romana
    Scalzulli, Potito Rosario
    Scarfo, Lydia
    Minoia, Carla
    Murru, Roberta
    Sportoletti, Paolo
    Frigeri, Ferdinando
    Albano, Francesco
    Di Renzo, Nicola
    Sanna, Alessandro
    Laurenti, Luca
    Massaia, Massimo
    Cassin, Ramona
    Coscia, Marta
    Patti, Caterina
    Pennese, Elsa
    Tafuri, Agostino
    Chiarenza, Annalisa
    Galieni, Piero
    Perbellini, Omar
    Selleri, Carmine
    Califano, Catello
    Ferrara, Felicetto
    Cuneo, Antonio
    Murineddu, Marco
    Palumbo, Gaetano
    Scortechini, Ilaria
    Tedeschi, Alessandra
    Trentin, Livio
    Varettoni, Marzia
    Pane, Fabrizio
    Liberati, Anna Marina
    Merli, Francesco
    Morello, Lucia
    Musuraca, Gerardo
    Tani, Monica
    Ibatici, Adalberto
    Regazzoni, Giulia
    Di Candia, Michele
    Palma, Maria
    Arienti, Danilo
    Molica, Stefano
    CANCERS, 2024, 16 (06)
  • [50] Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort
    Martino, Enrica Antonia
    Mauro, Francesca Romana
    Reda, Gianluigi
    Laurenti, Luca
    Visentin, Andrea
    Frustaci, Annamaria
    Vigna, Ernesto
    Pepe, Sara
    Catania, Gioacchino
    Loseto, Giacomo
    Murru, Roberta
    Chiarenza, Annalisa
    Sportoletti, Paolo
    Del Principe, Maria Ilaria
    Laureana, Roberta
    Coscia, Marta
    Galimberti, Sara
    Ferretti, Eleonora
    Zucchetto, Antonella
    Bomben, Riccardo
    Polesel, Jerry
    Tedeschi, Alessandra
    Rossi, Davide
    Trentin, Livio
    Neri, Antonino
    Morabito, Fortunato
    Gattei, Valter
    Gentile, Massimo
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
12345